ANNOUNCING
A Breath of Hope’s 2022
Peg’s Fight for Life Research Award $150,000


A Breath of Hope Lung Foundation
P.O. Box 387
Wayzata, MN 55391
research@abreathofhope.org
www.abreathofhope.org

A Breath of Hope Lung Foundation works to improve the five-year lung cancer survival rate by funding innovative research, educating the public for earlier detection, and supporting patients with services and critical disease education.

History: A Breath of Hope Lung Foundation (ABOHLF) was founded in 2008 by a group of Minnesota lung cancer patients and their caregivers after they organized a race to raise awareness about the world’s deadliest cancer - lung cancer. Each of the founders, whether they smoked or not, were shocked to learn that this disease carries a societal stigma that leaves families coping with blame, shame, misinformation, and inadequate research funding levels. ABOHLF has now invested close to two and a half million dollars in its research program, including many projects focused on improving early detection and late-stage treatments. ABOHLF serves thousands of U.S. lung cancer patients each year with rides to treatment, support groups, and patient education.

Nonprofit EIN #: 30-0475578

Accountability: A Breath of Hope Lung Foundation meets or exceeds all accountability standards through the Charities Review Council of Minnesota and was found to be fully compliant in its 2020 audit.

Purpose of Award
A Breath of Hope Lung Foundation (ABOHLF) will provide funding to the winning clinical investigator in the form of a $150,000 award paid every six months for two years. The award is designed to support salaries and other costs related to retaining research talent in the field of lung cancer. Lung cancer is the
A Breath of Hope Lung Foundation (ABOHLF), in collaboration with its panel of experts in the field of oncology, will evaluate the merit of research proposals submitted in response to the request for proposals announcement (RFP) from applicants who meet the following eligibility requirements.

**RFP ELIGIBILITY includes the following criteria:**
- Special consideration of early career investigators: if in first seven years of faculty position, a mentor is required
- Must hold a doctoral degree (MD, PhD, DO, DrPH, or equivalent)
- Must be employed by a U.S. research institution (proof of Visa required)
- If project involves people or animals, you must have received approval from your institution’s review board before the funds are disbursed
- Special consideration to early career investigators, including those who have not yet procured federal funding

Preferred topic: Specifically, proposals that address major questions addressing common mutated lung cancers is required. **Topic areas include, but are not limited to the following ideas:**
- Strategies to overcome resistance to immunotherapy in EGFR mutated lung cancer.
- Predictive and prognostic markers to identify responders and non-responders; and
- Approaches to overcome acquired resistance to targeted therapies
- Novel approaches to treating CNS mets in mutation-driven NSCLC
- Understanding mechanisms of resistance to immunotherapy in EGFR mutated lung cancer
• Improving prognostic value and predictive value for genetic heterogeneity across multiple mutation-positive NSCLC patients
• Identifying disease-causing variants in oncogenes for NSCLC patients that may benefit with targeted therapies

Eligibility summary: The principal investigators of proposals must have one of the following credentials: M.D., M.D./Ph.D., PhD, D.O., DrPH in a faculty appointment in a U.S. Research Institution. Researchers must be able to demonstrate protected time for cancer research through their letter from the institution.

The maximum period of performance is two years. The maximum allowable funding for the entire period of performance is $150,000.

I. TIMELINE FOR SUBMISSION AND REVIEW

Current RFP Timeline:
- Nov. 8, 2021: Announcement – Request for letter of inquiry (LOI)
- Dec. 15, 2021: Deadline for LOI submission – online forms reviewed by local ABOHLF research committee
- Jan. 17, 2022: Up to 15 investigators invited to submit full proposal
- March 15, 2022: Deadline for full proposal submission
- March–April 2022: National Scientific Advisory Committee scores 15 proposals;
- April 2022: ABOH Research Committee conducts phone interviews with finalists and their mentor
- April 25, 2022: Winner notified
- May 2, 2022: Winner announced; grant contract sent to institution.
- June 1, 2022: First payment of $37,500 to institution is mailed assuming institution has signed and returned ABOH grant contract

II. SUBMISSION PROCESS

Complete Eligibility & LOI form by clicking link found at www.abreathofhope.org/research

A one-page letter of intent is required by Dec. 15, 2021. Fifteen finalists will receive an invitation to apply by Jan. 17, 2022 and an online link to the full application will then be shared. The LOI must include PI credentials, name of mentor from institution, personal statement and specific aim.

Full proposals must be submitted by 11:59 p.m. CST March 15, 2022. Late submissions will not be considered. Applicants are encouraged to submit early because technical assistance will not be available past the close of the business day 12/15/20 – 5 p.m. CST. In case of technical difficulties, proposals are accepted by email as well as through the online form. ABOH Email address: research@abreathofhope.org.

Application Components:
1. **Contact Information:** Applicant and institution information, including phone and email.
2. **Project Information:** This section includes the following information about the proposed project:
   a. Project title
   b. Research focus area(s)
   c. Assurances for use of human and/or animal subjects in the research proposal
   d. Abstract – a brief abstract of the research proposal must be entered (<350 words)
3. **Specific Aims:** List succinctly the specific objectives of the research proposed, e.g., to test a stated hypothesis, create a novel design, solve a specific problem, challenge an existing paradigm or clinical
practice, address a critical barrier to progress in the field, or develop new technology. The specific aims should state concisely and realistically what the research intends to accomplish and/or what hypothesis is to be tested and should list measurable objectives for the proposed project.

4. **Personal Statement Questions:** Please answer briefly as the following questions in the text box areas on the online application. Each question has a maximum limit of 350 words.
   a. What is the applicant's career plan, including short- and long-term goals around lung cancer research?
   b. How would receiving this award affect the applicant's career in lung cancer research?
   c. What is the percentage of time the applicant spends on research activities?
   d. What is the applicant's role versus the mentor’s role in the proposed research study?
   e. What additional resources are available to support the applicant and the project?
   f. What are the other sources of salary support?
   g. Who will collect and analyze the data?
   h. What is the clinical potential of this research project?
   i. Was this research proposal submitted and/or will be submitted to other funding agencies/organizations?
   j. What additional responsibilities does the applicant have responsibility for during the two-year fellowship timeframe? Please list all non-research activities.

5. **Applicant’s NIH Biosketch:** Should include past, current and pending funding for their research. The biosketch must have no more than four pages.

6. **Research Strategy:** The research strategy should be limited to six (6) typewritten, single-spaced pages, with one-inch margins and 11-point Arial font type. ALL pertinent tables, pictures, and graphs MUST be included within the 6-page limit: The Research Strategy must contain the following information:
   a. **Significance and Background:**
      i. Explain the importance of the problem or critical barrier to progress in the field that the proposed project addresses.
      ii. Explain how the proposed project will improve scientific knowledge, technical capability, and/or critical practice in one or more broad fields.
      iii. Describe how the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field will change if the proposed aims are achieved.
   b. **Innovation:**
      i. Explain how the application challenges and seeks to shift current research or clinical practice paradigms.
      ii. Describe any novel theoretical concepts, approached or methodologies, instrumentation or interventions to be developed or used, and any advantage over existing methodologies, instrumentation, or interventions.
      iii. Explain any refinements, improvements, or new applications of theoretical concepts, approaches or methodologies, instrumentation, or interventions.
   c. **Approach and Feasibility:**
      i. Describe the overall strategy, methodology, and analyses to be used to accomplish the specific aims of the project. Include how the data will be collected, analyzed, and interpreted as well as any resource sharing plans as appropriate.
      ii. Discuss potential problems, alternative strategies, and benchmarks for success anticipated to achieve the aims.
iii. If the project is in the early stages of development, describe any strategy to establish feasibility, and address the management of any high-risk aspects of the proposed work.

iv. Please include appropriate detail and/or documentation in the Supporting Documentation section to assure a reviewer that your project is feasible in the timeframe of the grant. Examples include: a letter confirming you will have access to an experimental therapy or an approval letter from CTEP or a cooperative group.

v. Clearly state the applicant’s role in the project (i.e. writing of protocol, performing the assays, etc.).

vi. When human subjects are involved, the precautions to ensure patient safety and confidentiality and the relevance or implications for patient care should be explained.

vii. List and describe the facilities and resources available to conduct the study, including a description of industry support for any clinical trials.

d. **Statistical Analysis:** A statistical consideration section is required for all applications. This section should include the primary objective/hypothesis and primary endpoint of the study, justification of the proposed study sample size, procedures for data analysis, and appropriate statistical considerations. Any laboratory-based in vitro research aims should also include the primary objective/hypothesis and primary endpoint of the study, procedures for data analysis, and appropriate statistical details that describe the summary measures that will be used to meet the objectives of the study. It is highly recommended that you consult with a biostatistician before you submit your application.

e. **Cited References.** A list of cited references in the Research Strategy should be added and does not account for six-page limits.

7. **Institutional Letter of Support.** A letter from the Department Chair or Dean at the sponsoring institution where the applicant’s research project will be conducted must be provided. This letter must include a statement of institutional support that will enable the applicant to perform the proposed research. If the mentor is the Department Chair, the Institutional Letter of Support must come from the Dean.

8. **Clinical Protocol (optional).** If your project involves a clinical protocol, you are highly encouraged to add a copy of the protocol.

9. **Prior Publications (optional)** – Up to two prior publications may be included. The applicant must be a co-author on these publications.

10. **Supporting Documentation (optional).** This section may be used to upload any necessary additional information required to properly review the application (i.e. a letter from a drug company that they will provide the investigational drug, a letter of collaboration from another laboratory providing expertise for this project, etc.). Applicants are encouraged to provide a letter of support for any investigational agents.

11. **Project Timeline.** Enter major milestones for your project, the expected completion date, and if there is an associated deliverable. A deliverable is something that can be included in a progress report, such as a publication or an approval letter. You are not required to have deliverables. However, the timeline should make it clear what outcomes will be achieved during the grant award period.

12. **Budget and Justification.** The award funds will be directed to the sponsoring institution and should be used towards salary support, personnel, supplies, and other necessary expenses (excluding equipment) for the pursuit of the recipient’s research project. The budget must be directly entered into the ABOHLF budget form found at the end of this RFP. Budget justification for the entire project period must be entered for each line item requested in the “Notes” section.
13. **Letter of Support from a Mentor** - for investigators in their first seven years of a faculty position. This should include the following information:
   a. Training plan for the applicant, including intended structure of the mentor/investigator interaction during the proposed investigation;
   b. Confirmation that the applicant is *within the first ten years of a full-time* faculty appointment;
   c. A critical review of both the applicant and the research proposal;
   d. The role(s) or anticipated role(s) the applicant holds (will hold) at the institution;
   e. The level of institutional commitment to the applicant’s research program as an independent clinical investigator; and
   f. Assurance that the applicant’s sponsoring institution will provide adequate facilities and support for performance of the proposed work.

14. **Institutional Approval.** The Authorized Official representing the institution of the applicant must approve the completed application (both the project proposal and the budget) before submission. This official is normally from the institution’s Office of Sponsored Research and can be submitted as a letter of approval.

15. **Human Participants Certification.** If applicable, the applicant must provide verification of project approval from the institution’s ethical review board, or notification to ABOHLF if approval is pending.

**Additional Information:**
- **Use of fellowship funds** - The ABOH Research Fellowship is designed to be used for salary costs and approved fringe costs for the principle researcher.
- **Change of employment** - ABOHLF will have final approval rights of any change of sponsoring institution. Request to continue receiving funding must be submitted in writing to research@abreathofhope.org.
- **Progress Reports** – Two progress reports (one for lay audience to be shared publicly; one for research committee to be held in confidence) are due two weeks before each fellowship payment is mailed with one final report at end of cycle. **Due dates:**
  - By Nov. 15, 2022
  - By May 15, 2023
  - By Nov. 15, 2023
  - Final progress report due by May 15, 2024
- **Leave of absence** - A written request must be submitted to *A Breath of Hope Lung Foundation* (ABOHLF) Research Committee and permission shall be granted at the discretion of ABOHLF. If permission is not granted, unused funds will be returned to ABOHLF.
- **Patient and Intellectual property** – The sponsoring institution agrees to notify ABOHLF at research@abreathofhope.org in the case of patent applications or decisions to seek legal protection for intellectual property. ABOHLF will keep all information confidential. Any expenses related to patents shall fall on the sponsoring institution. The patent policies of the sponsoring institution shall guide all discoveries or intellectual properties that result from support of fellowship recipient.
- **Confidentiality** – Other than lay reports produced by PI’s, All *A Breath of Hope Research Fellowship* applications, progress reports and scoring are held confidential by ABOHLF. Submitted proposals become the property of ABOHLF and will not be returned.
• **Disclaimer** - *A Breath of Hope Lung Foundation* does not discriminate on the basis of gender, race, creed, religion, sexual orientation, disability, nationality, age or any other factors that are irrelevant to the quality of the research project being accomplished by applicants.

For questions about the fellowship competition, please contact Nancy Torrison at ABOHLF: [research@abreathofhope.org](mailto:research@abreathofhope.org) or 952-807-6111